1. Kurtzke, JF . A reassessment of the distribution of multiple sclerosis. Acta Neurol Scand 1975; 51: 137–157.
Google Scholar | Crossref | Medline2. Kurtzke, JF . Multiple sclerosis in time and space–geographic clues to cause. J Neurovirol 2000; 6 : S134–S140.
Google Scholar | Medline | ISI3. Brück, W, Gold, R, Lund, BT, et al. Therapeutic decisions in multiple sclerosis: moving beyond efficacy. JAMA Neurol 2013; 70: 1315–1324.
Google Scholar | Medline4. Pourcher, V . What are the infectious risks with disease-modifying drugs for multiple sclerosis and how to reduce them? A review of literature. Rev Neurol (Paris) 2020; 176: 235–243.
Google Scholar | Crossref | Medline5. Grebenciucova, E, Pruitt, A. Infections in patients receiving multiple sclerosis disease-modifying therapies. Curr Neurol Neurosci Rep 2017; 17: 88.
Google Scholar | Crossref | Medline6. Luna, G, Alping, P, Burman, J, et al. Infection risks Among patients With multiple sclerosis treated With fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 2020; 77: 184–191.
Google Scholar | Crossref | Medline7. Celius, EG . Infections in patients with multiple sclerosis: implications for disease-modifying therapy. Acta Neurol Scand 2017; 136 : 34–36.
Google Scholar | Crossref | Medline8. Montgomery, S, Hillert, J, Bahmanyar, S. Hospital admission due to infections in multiple sclerosis patients. Eur J Neurol 2013; 20: 1153–1160.
Google Scholar | Crossref | Medline | ISI9. Moiola, L, Barcella, V, Benatti, S, et al. The risk of infection in patients with multiple sclerosis treated with disease-modifying therapies: a delphi consensus statement. Mult Scler 2021; 27: 331–346.
Google Scholar | SAGE Journals | ISI10. Rommer, PS, Zettl, UK. Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients. Expert Opin Pharmacother 2018; 19: 483–498.
Google Scholar | Crossref | Medline11. Epstein, DJ, Dunn, J, Deresinski, S. Infectious complications of multiple sclerosis therapies: implications for screening, prophylaxis, and management. Open Forum Infect Dis 2018; 5: ofy174.
Google Scholar | Crossref | Medline12. Reddy, KR, Beavers, KL, Hammond, SP, et al. American Gastroenterological association institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215–219; quiz e16–17.
Google Scholar | Crossref | Medline13. Bittner, S, Engel, S, Lange, C, et al. [Diagnostics and treatment of tuberculosis under immunotherapy for multiple sclerosis : current status and recommendations in Germany]. Nervenarzt 2019; 90: 1245–1253.
Google Scholar | Crossref | Medline14. Navas, C, Torres-Duque, CA, Munoz-Ceron, J, et al. Diagnosis and treatment of latent tuberculosis in patients with multiple sclerosis, expert consensus. On behalf of the Colombian association of neurology, committee of multiple sclerosis. Mult Scler J Exp Transl Clin 2018; 4: 2055217317752202.
Google Scholar | SAGE Journals15. Persson, R, Lee, S, Ulcickas Yood, M, et al. Infections in patients diagnosed with multiple sclerosis: a multi-database study. Mult Scler Relat Disord 2020; 41: 101982.
Google Scholar | Crossref | Medline16. Mack, U, Migliori, GB, Sester, M, et al. LTBI: latent tuberculosis infection or lasting immune responses to M. tuberculosis? A TBNET consensus statement. Eur Respir J 2009; 33: 956–973.
Google Scholar | Crossref | Medline | ISI17. Ho, P-R, Koendgen, H, Campbell, N, et al. Risk of natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: a retrospective analysis of data from four clinical studies. Lancet Neurol 2017; 16: 925–933.
Google Scholar | Crossref | Medline18. Ciardi, MR, Zingaropoli, MA, Iannetta, M, et al. JCPyv NCCR analysis in PML patients with different risk factors: exploring common rearrangements as essential changes for neuropathogenesis. Virol J 2020; 17: 23.
Google Scholar | Crossref | Medline19. Ahmad, M, Ibrahim, WH, Sarafandi, SA, et al. Diagnostic value of bronchoalveolar lavage in the subset of patients with negative sputum/smear and mycobacterial culture and a suspicion of pulmonary tuberculosis. Int J Infect Dis 2019; 82: 96–101.
Google Scholar | Crossref | Medline20. Ciardi, MR, Iannetta, M, Zingaropoli, MA, et al. Reactivation of hepatitis B virus With immune-Escape mutations after ocrelizumab treatment for multiple sclerosis. Open Forum Infect Dis 2019; 6: ofy356.
Google Scholar | Crossref | Medline21. Fragoso, YD, Adoni, T, Anacleto, A, et al. How do we manage and treat a patient with multiple sclerosis at risk of tuberculosis? Expert Rev Neurother 2014; 14: 1251–1260.
Google Scholar | Crossref | Medline | ISI22. Riva, A, Barcella, V, Benatti, SV, et al. Vaccinations in patients with multiple sclerosis: a delphi consensus statement. Mult Scler 2021; 27: 347–359.
Google Scholar | SAGE Journals | ISI23. Farez, MF, Correale, J, Armstrong, MJ, et al. Practice guideline update summary: vaccine-preventable infections and immunization in multiple sclerosis: report of the guideline development, dissemination, and implementation subcommittee of the American academy of neurology. Neurology 2019; 93: 584–594.
Google Scholar | Crossref | Medline24. Yong, KP, Kim, HJ. Disease modifying therapies and infection risks in multiple sclerosis-a decision-making conundrum. Ann Transl Med 2020; 8: 722.
Google Scholar | Crossref | Medline25. Klotz, L, Havla, J, Schwab, N, et al. Risks and risk management in modern multiple sclerosis immunotherapeutic treatment. Ther Adv Neurol Disord 2019; 12: 1756286419836571.
Google Scholar | SAGE Journals | ISI26. Syed, YY . Recombinant zoster vaccine (shingrix ®): a review in herpes zoster. Drugs Aging 2018; 35: 1031–1040.
Google Scholar | Crossref | Medline27. Miller, G, Grogan, E, Rowe, D, et al. Selective lack of antibody to a component of EB nuclear antigen in patients with chronic active epstein-barr virus infection. J Infect Dis 1987; 156: 26–35.
Google Scholar | Crossref | Medline28. Berger, JR . Classifying PML risk with disease modifying therapies. Mult Scler Relat Disord 2017; 12: 59–63.
Google Scholar | Crossref | Medline29. Pfender, N, Jelcic, I, Linnebank, M, et al. Reactivation of herpesvirus under fingolimod: a case of severe herpes simplex encephalitis. Neurology 2015; 84: 2377–2378.
Google Scholar | Crossref | Medline | ISI